首页> 外文会议>Annual Meeting of the European Society of Animal Cell Technology >The spp biotech module 1: proteins for amedical applications a multidisciplinary effort for the development of a recombinant anti-RhD antibody preparation for the prevention of Hemolytic Disease of the Newborn
【24h】

The spp biotech module 1: proteins for amedical applications a multidisciplinary effort for the development of a recombinant anti-RhD antibody preparation for the prevention of Hemolytic Disease of the Newborn

机译:SPP Biotech模块1:用于AMEDICY应用的蛋白质,用于开发重组抗RHD抗体制剂的多学科努力,用于预防新生儿的溶血性疾病

获取原文

摘要

Hemolytic Disease of the Newborn (HDN) can be a life threatening condition in Rh D positive babies born from Rh D negative mothers. For several decades, prophylactic treatment with immunoglobulins derived from human blood plasma from immunized donors has been available. Because of concerns for donor safety and limited supply of raw material, alternatives for production of specific immunoglobulins were investigated. Since 1994 ZLB has, in collaboration with a group at the University Hospital in Bern, started to develop recombinant anti-D antibodies. In 1997, a multidisciplinary team with expertise ranging from molecular biology to biochemical engineering for large scale operations was constituted, co-funded by the Swiss National Science Foundation and ZLB, as the industrial partner. The aims of this team are to establish the prophylactic principle and the manufacturing process for anti-D therapy based on recombinant antibody preparations produced from Chinese hamster ovary (CHI) cells.
机译:新生儿(HDN)的溶血性疾病可以是RH D消极母亲出生的RH D阳性婴儿的危及危及疾病状态。几十年来,已有来自免疫供体的来自人血浆的免疫球蛋白的预防性处理。由于施主安全和原料供应有限的担忧,研究了特异性免疫球蛋白的生产替代品。自1994年以来,ZLB与伯尔尼大学医院的一组合作开始开发重组抗D抗体。 1997年,一个具有专业知识的多学科团队,从分子生物学到大规模行动的生化工程,由瑞士国家科学基金会和ZLB为工业伴侣共同资助。该团队的目的是建立基于来自中国仓鼠卵巢(CHI)细胞生产的重组抗体制剂的预防性原理和抗D治疗的制造方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号